Geode Capital Management LLC Acquires 28,517 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,510,568 shares of the specialty pharmaceutical company's stock after purchasing an additional 28,517 shares during the period. Geode Capital Management LLC owned 2.74% of Supernus Pharmaceuticals worth $54,633,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $6,847,000. Great Lakes Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $6,131,000. Norges Bank purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at approximately $4,540,000. American Century Companies Inc. increased its position in Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after buying an additional 95,777 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Supernus Pharmaceuticals by 79.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 174,916 shares of the specialty pharmaceutical company's stock valued at $6,325,000 after buying an additional 77,393 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SUPN shares. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded up $0.05 during trading hours on Friday, hitting $30.76. The company had a trading volume of 476,313 shares, compared to its average volume of 493,446. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of 28.75 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a 50 day simple moving average of $32.76 and a 200 day simple moving average of $35.01.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.